Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
2 Recession-Proof Dividend Stocks to Buy and Hold
05:25am, Thursday, 27'th Mar 2025
Fears of a looming recession seem to be rising, partly fueled by President Donald Trump's macroeconomic policies. While it's impossible to predict whether an economic downturn is indeed coming, it's n
Strategically Building A $100,000 Dividend Portfolio For Attractive Income And Strong Risk-Adjusted Returns
06:00pm, Wednesday, 26'th Mar 2025
The Dividend Income Accelerator Portfolio focuses on financially healthy companies with strong balance sheets, aiming to generate sustainable dividend income and reduce portfolio volatility. Recent ad
The Big 3: JNJ, GE, LULU
12:30pm, Wednesday, 26'th Mar 2025
Healthcare headwinds have @Theotrade's Don Kaufman leaning bearish on Johnson & Johnson (JNJ) while staying bullish in GE Aerospace (GE) despite hitting 18-year highs today. He offers options trades i
Median overall survival not yet reached with projected improvement of more than one year versus osimertinib RARITAN, N.J. , March 26, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announce
Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock
10:45am, Wednesday, 26'th Mar 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:51am, Wednesday, 26'th Mar 2025
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Oral presentation features new data from the 24-week pivotal Vivacity-MG3 study which show sustained disease control through treatment with nipocalimab on the clinician-assessed QMGa score in antibody
Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts
06:50pm, Monday, 24'th Mar 2025
The latest trading day saw Johnson & Johnson (JNJ) settling at $163.29, representing a -0.21% change from its previous close.
BofA reveals stocks with a history of steady returns amid market volatility
03:31pm, Monday, 24'th Mar 2025
Trump tariffs have already hurt US stocks significantly in recent weeks but the Fed's latest warning of stickier inflation and an economic slowdown ahead signals the worst may not be over just yet.
Here's How to Play JNJ Stock as it Announces $55B US Investment Plan
07:35am, Monday, 24'th Mar 2025
Those who own JNJ stock may stay invested for some time, as the company is optimistic about a better performance in 2025.
J&J to Invest $55B in United States to Boost Manufacturing, R&D
07:30am, Monday, 24'th Mar 2025
JNJ announces plans to invest more than $55 billion over the next four years to expand its manufacturing footprint in the United States.
2 Dividend Picks Yielding Up To 5.67% For A Balanced Income & Growth Portfolio
06:00pm, Saturday, 22'nd Mar 2025
I have added Canadian Natural Resources and NextEra Energy to The Dividend Income Accelerator Portfolio, each representing 2.19% of our overall portfolio. These strategic acquisitions help us to furth
2025 Dividend Kings: Strong Run Continues
12:59pm, Friday, 21'st Mar 2025
The Dividend Kings are outperforming the S&P 500 in 2025 by 4.57%. Top performers include National Fuel & Gas (+30.21%), Consolidated Edison (+22.66%), and AbbVie (+20.40%). Promising Dividend Kings i
J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's Disease
09:31am, Friday, 21'st Mar 2025
FDA approves J&J's Tremfya for its fourth indication and the second IBD condition.
FDA Approves Johnson & Johnson's Tremfya For Crohn's Disease
08:23am, Friday, 21'st Mar 2025
On Thursday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson's (NYSE JNJ) Tremfya (guselkumab), the first and only IL-23 inhibitor offering subcutaneous (SC) and intravenous (
